Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i2.30
pages 131-148

Treatment of Hepatitis C Virus Infection With Interferon and Small Molecule Direct Antivirals: Viral Kinetics and Modeling

Libin Rong
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico
Alan S. Perelson
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico


Hepatitis C virus (HCV) infection remains a threat to global public health. Treatment with pegylated interferon (IFN) plus ribavirin leads to a sustained virologic response in about 50% of patients. New therapies using direct antiviral agents have the potential to cure patients unresponsive to IFN-based therapies. Mathematical modeling has played an important role in studying HCV kinetics. Using models, one can evaluate the effectiveness of new treatment agents, estimate important parameters that govern virus-host interactions, explore possible mechanisms of drug action against HCV, investigate the development of drug resistance, and study quasispecies dynamics during therapy. Here we review our current knowledge of HCV kinetics under IFN-based therapy and newly developed antiviral agents specifically targeted to attack HCV, and show how mathematical models have helped to improve our understanding of HCV infection and treatment.

Articles with similar content:

Emerging Trends in Non-Interferon-Based Genotype-Specific Antiviral Agents: Pharmaceutical Perspectives
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Tahir Farooq, Muhammad Ibrahim, Tahsin Gulzar, Matloob Ahmed, Muhammad Sajid Hamid Akash, Arruje Hameed, Kanwal Rehman
Drug Development for Metastasis Prevention
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Steven M. Dubinett, Yari Fontebasso
Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma
Critical Reviews™ in Biomedical Engineering, Vol.40, 2012, issue 4
Frank O. Nestle, Louise Saul, Sophia N. Karagiannis, Sophia Tsoka, Debra H. Josephs, Chrysanthi Ainali, Panagiotis Karagiannis
Options and Opportunities for Clinical Management and Treatment of Psoriasis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 1
Udita Agrawal, Devyani Dube, Madhu Gupta, Suresh P. Vyas
Molecular Networks in Drug Discovery
Critical Reviews™ in Biomedical Engineering, Vol.38, 2010, issue 2
John Kenneth Morrow, Longzhang Tian, Shuxing Zhang